Session: Innovative Pharma Excipient Hyaluronic Acid Nanogel (Sonanos™) for Solubilization, Sustained Release and Lymph Node Delivery
Tech Forum Innovative Pharma Excipient Hyaluronic Acid Nanogel (Sonanos) for Solubilization, Sustained Release and Lymph Node Delivery
Thursday, July 11, 2024
8:00 AM – 9:00 AM CET
Location: Emilia
Sponsored By
There is a growing trend in drug discovery towards higher molecular weight modalities (e.g., peptides or proteins). However, this shift presents some formulation challenges such as poor solubility and limited oral absorption. In order to address these challenges, there is a rising need for formulation technologies that can enhance solubility for injections or enable sustained release, ultimately aiming to reduce the burden on patients.
These challenges and demands have motivated us to investigate a novel pharma excipient called hyaluronic acid nanogel (Sonanos™). The Sonanos™ contains nano-sized hydrogel particles composed of Cholesterol-Modified Hyaluronic Acid; the particle size in water ranges from 20-100nm. Interestingly, the Sonanos™ dissolved in water can encapsulate various types of APIs, including peptides or proteins, by simple addition of API and subsequent mixing, allowing it to act as a API carrier.
We, Asahi Kasei Corporation, have developed proprietary industrial manufacturing technology for Sonanos™, which aims for commercialization. As the versatility towards various modalities and the facile encapsulation process enables us to collaborate with various pharmaceutical companies, we welcome passionate collaborators who would like to try our Sonanos™ to develop innovative formulations.
In this presentation, we will present details of our Sonanos™ technologies and some examples demonstrating how the Sonanos™ facilitates solubilization, sustained release or lymph node delivery of APIs.
